As more and more AI companies reorient their focus to develop technology to fight Covid-19, Mumbai-based AI startup Qure.ai is on its way to launching two critical offerings. The team has been directing its R&D efforts and using past experience in the domain of AI and healthcare to help medical professionals tackle Covid-19.
Operating in the domain of radiology, Qure.ai has been refining medical imaging accuracy with the assistance of machine-supported tools trained using millions of images. Aimed at medical imaging professionals, this AI solution developer taps deep learning technologies to provide automated interpretation of radiology exams, including X-rays, CTs and MRI scans.
Qure.ai’s solutions for Covid-19 include:
- A tool that can interpret an X-ray to detect Covid-19, as well as quantify the proportion of lungs affected. This can be used to monitor the progression of patients, as well as to screen patients who need to undergo further testing.
- An app-based solution which can be used for contact tracing of patients. It can also enable radiologists to effectively triage medical cases.
Thus, by enabling faster diagnosis and cost-effective solutions, it can greatly help healthcare providers who are working in the frontline amid the coronavirus pandemic.
Targeting not just medical professionals, but also high-risk populations – especially the elderly and those with pre-existing conditions – Qure.ai is available to chat with users 24/7 across time zones to offer help in this critical time.
By scheduling an appointment, you can also share solutions and explore a partnership opportunity. In fact, the startup recently announced its strategic partnership with UK market leader Medica Group to develop AI tools to improve efficiency of radiology scan workload.
Tuberculosis to Covid-19
Qure.ai’s experience with tackling tuberculosis (TB) in more than 10 countries has greatly helped them develop this solution. This tool was originally designed to interpret chest X-rays as a way to screen for tuberculosis and other lung diseases.
What sets this solution apart is not just its affordability, but also because it significantly reduces the time taken to diagnosis.
Furthermore, in a big boost to the potential of AI in healthcare, Qure.ai recently secured $16 million from Sequoia Capital and MassMutual Ventures to further invest into R&D.
